Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
about
Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transportExploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolonesCharacterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaContribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniaeAssessing sensitivity to antibacterial topoisomerase II inhibitors.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusActivity of and resistance to moxifloxacin in Staphylococcus aureus.Novel antibacterial agents for the treatment of serious Gram-positive infections.Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Mechanisms of resistance to quinolones.Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.Mechanism of quinolone action and resistance.Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae.Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.Trends in antibiotic resistance in bacterial keratitis isolates from South India.Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.Immunomodulatory activities of gemifloxacin in mice.Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones.Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinProbing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IVClerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage.Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage.Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.Electronic Structure, Nonlinear Optical Properties, and Vibrational Analysis of Gemifloxacin by Density Functional Theory
P2860
Q27679776-E4538C7A-D7E8-41E0-BA81-8CFD07410076Q28828291-109FF9BD-4B29-43F4-9333-96CC805EA76DQ33663032-F3CA8E4E-F887-4B0C-9343-BA85980A7B36Q33757558-7C0EFA32-0E13-4412-866D-84167AE39F91Q33771873-35151E10-998A-48D4-87A3-E41671BC9D3DQ34142238-9E6C5DC0-F2A3-4868-9AAF-25DDF0C71C45Q34725095-49803D39-D1B5-439D-B6E9-5A92A4E23D4FQ34885313-1B6DEE1A-372E-43C3-B06E-6E7CF03A77AAQ35073345-9AE641D6-E34B-4CE7-84A7-83A351CB75A9Q35798789-19366D2B-FE96-48EC-A6C8-163A5672F291Q36155441-86C5A4FE-B6A0-4D26-B47F-2FDFD050B80FQ37488687-CB5A800D-BCA5-46E7-BA01-8D36941FDA3DQ37594797-9F8E7E7D-0FE5-489F-8101-C4C576431266Q37701591-69E37302-7051-4465-8B8D-BBE2AF15014CQ38455501-9113829A-11D0-43DE-9287-520F3592D0BAQ38523119-4B053BF8-A250-46F1-877E-83B6A006AFF4Q40693098-76D2B7DC-DEA0-428F-A768-B067CBED4AFBQ40882705-CC0D5F17-79F7-41D9-B95E-E912678DF3BFQ41580708-55ECF8F1-DAFA-4F3C-8BB1-2E2223462A29Q41670488-516D3136-32A4-4A88-9B73-6AA6E1BCBE87Q41848451-41E97A01-C4A2-4FBF-9EEA-11AEEA3DD5D8Q41925162-5CCC3D50-7EEB-4B6D-B2BF-11A4533BF6EAQ42078632-8881BF87-AB19-4E94-A9E1-19EDBA59C8CCQ42111571-EE0FF15D-BD41-4E10-9F7E-2F88D800FDE6Q42264322-E17133F0-F64C-43E3-A54F-03C9F08F7C30Q42513426-CA69BC35-A5B4-4D02-8DCB-6F3533F06A91Q42872445-B7E808F5-091C-46FD-AB31-69C2357E0C8DQ45230495-429217F9-13F5-47CF-BBDC-14C56C32F0A4Q58911199-74B3FEE2-5BF1-4E29-97CF-98B825F3012D
P2860
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Cleavable-complex formation by ...... in and other fluoroquinolones.
@en
Cleavable-complex formation by ...... in and other fluoroquinolones.
@nl
type
label
Cleavable-complex formation by ...... in and other fluoroquinolones.
@en
Cleavable-complex formation by ...... in and other fluoroquinolones.
@nl
prefLabel
Cleavable-complex formation by ...... in and other fluoroquinolones.
@en
Cleavable-complex formation by ...... in and other fluoroquinolones.
@nl
P2093
P2860
P1476
Cleavable-complex formation by ...... in and other fluoroquinolones.
@en
P2093
Genoveva Yague
Julia E Morris
Katherine A Gould
L Mark Fisher
Xiao-Su Pan
P2860
P304
P356
10.1128/AAC.46.2.413-419.2002
P407
P577
2002-02-01T00:00:00Z